About
Kinimmune develops localized immunotherapy treatments using proprietary peptide-TLR agonists to activate the immune system at tumor sites and improve responses in solid tumor cancer patients.
Explore Kinimmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.